15 results on '"Debelleix, S."'
Search Results
2. Atteinte respiratoire précoce dans la mucoviscidose
- Author
-
Fayon, M., Ladipo, Y., Galodé, F., Debelleix, S., and Reix, P.
- Published
- 2016
- Full Text
- View/download PDF
3. Les anti-leucotriènes dans la prise en charge de l’asthme selon l’âge
- Author
-
Debelleix, S.
- Published
- 2012
- Full Text
- View/download PDF
4. Alternatives à la corticothérapie inhalée dans le traitement de l’asthme de l’enfant : les anti-leucotriènes
- Author
-
Fayon, M., primary, Feret, V., additional, Sagbo, G., additional, and Debelleix, S., additional
- Published
- 2014
- Full Text
- View/download PDF
5. 82 Secondary prophylactic antibiotics against Staphylococcus aureus (Sa) during the winter months in children with cystic fibrosis
- Author
-
Ferret, V., primary, Bui, S., additional, Clouzeau, H., additional, Debelleix, S., additional, Christoflour, N., additional, Valentin, F., additional, Bouvier, C., additional, and Fayon, M., additional
- Published
- 2013
- Full Text
- View/download PDF
6. Les conséquences de la sensibilisation allergénique sur la réactivité bronchique et le remodelage des voies aériennes sont exacerbées chez la souris immature
- Author
-
Debelleix, S., primary
- Published
- 2008
- Full Text
- View/download PDF
7. Non-invasive respiratory support in children and young adults with complex medical conditions in pediatric palliative care.
- Author
-
Fauroux B, Taytard J, Ioan I, Lubrano M, Le Clainche L, Bokov P, Dudoignon B, Debelleix S, Galode F, Coutier L, Sigur E, Labouret G, Ollivier M, Binoche A, Bergougnioux J, Mbieleu B, Essid A, Hullo E, Barzic A, Moreau J, Jokic M, Denamur S, Aubertin G, and Schweitzer C
- Abstract
Objective: Dyspnoea and sleep-disordered breathing (SDB) are common in children with life-limiting conditions but studies on treatment with non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP) are scarce. The aim of the study was to describe children treated with long-term NIV/CPAP within a paediatric palliative care programme in France., Methods: Cross-sectional survey on children and young adults with complex medical conditions treated within the French paediatric NIV network with long-term NIV/CPAP. Characteristics of the patients were analysed and patient-related outcome measures of NIV/CPAP benefit were reported., Results: The data of 50 patients (68% boys), median age 12 (0.4-21) years were analysed. Twenty-three (46%) patients had a disorder of the central nervous system and 5 (10%) a chromosomal anomaly. Thirty-two (64%) patients were treated with NIV and 18 (36%) with CPAP. NIV/CPAP was initiated on an abnormal Apnoea-Hypopnoea Index in 18 (36%) of the patients, an abnormal nocturnal gas exchange alone in 28 (56%), and after an acute respiratory failure in 11 (22%) of the patients. Mean objective NIV/CPAP adherence was 9.3±3.7 hours/night. NIV/CPAP was associated with a decrease in dyspnoea in 60% of patients, an increase in sleep duration in 60% and in sleep quality in 74%, and an improvement in parents' sleep in 40%., Conclusions: In children with life-limiting conditions, long-term NIV/CPAP may be associated with relief of dyspnoea, an improvement of SDB and an improvement in parents' sleep., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
8. Long term noninvasive ventilation and continuous positive airway pressure in children with neuromuscular diseases in France.
- Author
-
Allaer L, Khirani S, Griffon L, Massenavette B, Bierme P, Aubertin G, Stremler N, Baravalle-Einaudi M, Mazenq J, Ioan I, Schweitzer C, Binoche A, Lampin ME, Mordacq C, Bergounioux J, Mbieleu B, Rubinsztajn R, Sigur E, Labouret G, Genevois A, Becourt A, Hullo E, Debelleix S, Galodé F, Bui S, Moreau J, Renoux MC, Matecki S, Lubrano Lavadera M, Heyman R, Pomedio M, Clainche LL, Bokov P, Dudoignon B, Masson A, Hangard P, Menetrey C, Jokic M, Gachelin E, Perisson C, Pervillé A, Fina A, Giovannini-Chami L, Fleurence E, Barzic A, Cros P, Breining A, Ollivier M, Labbé G, Coutier L, Taytard J, and Fauroux B
- Subjects
- Male, Child, Humans, Child, Preschool, Adolescent, Female, Continuous Positive Airway Pressure, Noninvasive Ventilation, Muscular Dystrophy, Duchenne complications, Muscular Dystrophy, Duchenne therapy, Neuromuscular Diseases complications, Neuromuscular Diseases therapy, Muscular Atrophy, Spinal
- Abstract
The aim of the study was to describe the characteristics of children with neuromuscular diseases treated with long term noninvasive ventilation or continuous positive airway pressure in France. On June 1st 2019, 387 patients (63% boys, mean age 11.2 ± 5.5 years) were treated with long term noninvasive ventilation/continuous positive airway pressure. Thirty three percent of patients had spinal muscular atrophy, 30% congenital myopathy/dystrophy, 20% Duchenne muscular dystrophy, 7% Steinert myotonic dystrophy, and 9% other neuromuscular diseases. Ninety-four percent of patients were treated with long term noninvasive ventilation and 6% with continuous positive airway pressure. Treatment was initiated electively for 85% of patients, mainly on an abnormal overnight gas exchange recording (38% of patients). Noninvasive ventilation/continuous positive airway pressure was initiated during a respiratory exacerbation in 15% of patients. Mean duration of noninvasive ventilation/continuous positive airway pressure was 3.3 ± 3.1 years. Mean objective long term noninvasive ventilation/continuous positive airway pressure use was 8.0 ± 3.1 h/24. Spinal muscular atrophy, congenital myopathy/dystrophy, and Duchenne muscular dystrophy represented 83% of children with neuromuscular diseases treated with long term noninvasive ventilation in France. Screening for nocturnal hypoventilation was satisfactory as noninvasive ventilation /continuous positive airway pressure was predominantly initiated electively., Competing Interests: Declaration of Competing Interest None., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
9. ROHHAD syndrome without rapid-onset obesity: A diagnosis challenge.
- Author
-
Desse B, Tran A, Butori M, Marchal S, Afanetti M, Barthélemy S, Bérard E, Baechler E, Debelleix S, Lampin ME, Macey J, Massenavette B, Harvengt J, Trang H, and Giovannini-Chami L
- Abstract
Background: ROHHAD syndrome (Rapid-onset Obesity with Hypothalamic dysfunction, Hypoventilation and Autonomic Dysregulation) is rare. Rapid-onset morbid obesity is usually the first recognizable sign of this syndrome, however a subset of patients develop ROHHAD syndrome without obesity. The prevalence of this entity is currently unknown. Alteration of respiratory control as well as dysautonomic disorders often have a fatal outcome, thus early recognition of this syndrome is essential., Material and Methods: A retrospective, observational, multicenter study including all cases of ROHHAD without rapid-onset obesity diagnosed in France from 2000 to 2020., Results: Four patients were identified. Median age at diagnosis was 8 years 10 months. Median body mass index was 17.4 kg/m
2 . Signs of autonomic dysfunction presented first, followed by hypothalamic disorders. All four patients had sleep apnea syndrome. Hypoventilation led to the diagnosis. Three of the four children received ventilatory support, all four received hormone replacement therapy, and two received psychotropic treatment. One child in our cohort died at 2 years 10 months old. For the three surviving patients, median duration of follow-up was 7.4 years., Conclusion: ROHHAD syndrome without rapid-onset obesity is a particular entity, appearing later than ROHHAD with obesity. This entity should be considered in the presence of dysautonomia disorders without brain damage. Likewise, the occurrence of a hypothalamic syndrome with no identified etiology requires a sleep study to search for apnea and hypoventilation. The identification of ROHHAD syndrome without rapid-onset obesity is a clinical challenge, with major implications for patient prognosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Desse, Tran, Butori, Marchal, Afanetti, Barthélemy, Bérard, Baechler, Debelleix, Lampin, Macey, Massenavette, Harvengt, Trang and Giovannini-Chami.)- Published
- 2022
- Full Text
- View/download PDF
10. The First 1000 Days: Impact of Prenatal Tobacco Smoke Exposure on Hospitalization Due to Preschool Wheezing.
- Author
-
Collet C, Fayon M, Francis F, Galode F, Bui S, and Debelleix S
- Abstract
Preschool wheezing and related hospitalization rates are increasing. Prenatal tobacco smoke exposure (PTSE) increases the risk of wheezing, yet >20% of French women smoke during pregnancy. In this observational retrospective monocentric study, we assessed the link between PTSE and hospital admissions. We included infants <2 years of age admitted for acute wheezing. A phone interview with mothers was completed by electronic records. The primary endpoint was the ratio of cumulative duration of the hospitalization stays (days)/age (months). 129 children were included (36.4% exposed to PTSE vs. 63.6% unexposed). There was a significant difference in the duration of hospitalization/age: 0.9 days/month (exposed) vs. 0.58 days/month (unexposed) ( p = 0.008). Smoking one cigarette/day during pregnancy was associated with an increase in hospitalization duration of 0.055 days/month (r = 0.238, p = 0.006). In the multi-variable analysis, this positive association persisted (β = 0.04, p = 0.04; standardized β = 0.27, p = 0.03). There was a trend towards a dose-effect relationship between PTSE and other important parameters associated with hospital admissions. We have demonstrated a dose-effect relationship, without a threshold effect, between PTSE and duration of hospitalization for wheezing in non-premature infants during the first 2 years of life. Prevention campaigns for future mothers should be enforced.
- Published
- 2021
- Full Text
- View/download PDF
11. Paediatric long term continuous positive airway pressure and noninvasive ventilation in France: A cross-sectional study.
- Author
-
Fauroux B, Khirani S, Amaddeo A, Massenavette B, Bierme P, Taytard J, Stremler N, Baravalle-Einaudi M, Mazenq J, Ioan I, Schweitzer C, Lampin ME, Binoche A, Mordacq C, Bergounioux J, Mbieleu B, Rubinsztajn R, Sigur E, Labouret G, Genevois A, Becourt A, Hullo E, Pin I, Debelleix S, Galodé F, Bui S, Moreau J, Renoux MC, Matecki S, Lavadera ML, Heyman R, Pomedio M, Le Clainche L, Bokov P, Masson A, Hangard P, Menetrey C, Jokic M, Gachelin E, Perisson C, Pervillé A, Fina A, Giovannini-Chami L, Fleurence E, Barzic A, Breining A, Ollivier M, Labbé G, Coutier L, and Aubertin G
- Subjects
- Adolescent, Age Factors, Airway Obstruction therapy, Child, Child, Preschool, Cross-Sectional Studies, Female, France epidemiology, Humans, Infant, Male, Patient Compliance statistics & numerical data, Sleep Apnea Syndromes therapy, Surveys and Questionnaires, Time Factors, Young Adult, Continuous Positive Airway Pressure statistics & numerical data, Noninvasive Ventilation statistics & numerical data
- Abstract
Objective: To describe the characteristics of children treated with long term continuous positive airway pressure (CPAP) or noninvasive ventilation (NIV) in France., Design: Cross-sectional national survey., Setting: Paediatric CPAP/NIV teams of 28 tertiary university hospitals in France., Patients: Children aged <20 years treated with CPAP/NIV since at least 3 months on June 1st, 2019., Intervention: An anonymous questionnaire was filled in for every patient., Results: The data of 1447 patients (60% boys), mean age 9.8 ± 5.8 years were analysed. The most frequent underlying disorders were: upper airway obstruction (46%), neuromuscular disease (28%), disorder of the central nervous system (13%), cardiorespiratory disorder (7%), and congenital bone disease (4%). Forty-five percent of the patients were treated with CPAP and 55% with NIV. Treatment was initiated electively for 92% of children, while 8% started during an acute illness. A poly(somno)graphy (P(S)G) was performed prior to treatment initiation in 26%, 36% had a P(S)G with transcutaneous carbon dioxide monitoring (PtcCO
2 ), while 23% had only a pulse oximetry (SpO2 ) with PtcCO2 recording. The decision of CPAP/NIV initiation during an elective setting was based on the apnea-hypopnea index (AHI) in 41% of patients, SpO2 and PtcCO2 in 25% of patients, and AHI with PtcCO2 in 25% of patients. Objective adherence was excellent with a mean use of 7.6 ± 3.2 h/night. Duration of CPAP/NIV was 2.7 ± 2.9 years at the time of the survey., Conclusion: This survey shows the large number of children treated with long term CPAP/NIV in France with numerous children having disorders other than neuromuscular diseases., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
12. Recommended respiratory tests are not routinely performed for mucopolysaccharidosis patients.
- Author
-
Denamur S, Touati G, Debelleix S, Damaj L, Barth M, Tardieu M, Gorce M, Broué P, Lacombe D, and Labarthe F
- Abstract
Recommended respiratory tests used as major outcomes in clinical trials for MPS treatment cannot be routinely performed in everyday practice because neurocognitive impairment and motor skill difficulties affect compliance for most MPS patients https://bit.ly/3G4qp8U., Competing Interests: Conflict of interest: D. Lacombe reports personal fees from Sanofi-Genzyme outside the submitted work. The other authors all declare no conflict of interest., (Copyright ©The authors 2022.)
- Published
- 2021
- Full Text
- View/download PDF
13. Montelukast reverses airway remodeling in actively sensitized young mice.
- Author
-
Debelleix S, Siao-Him Fa V, Begueret H, Berger P, Kamaev A, Ousova O, Marthan R, and Fayon M
- Subjects
- Age Factors, Allergens, Animals, Asthma physiopathology, Bronchoalveolar Lavage Fluid cytology, Cyclopropanes, Disease Models, Animal, Female, Lung drug effects, Lung physiopathology, Mice, Inbred BALB C, Ovalbumin, Sulfides, Acetates therapeutic use, Airway Remodeling drug effects, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy, Quinolines therapeutic use
- Abstract
Asthma is characterized by airway hyperresponsiveness (AHR) and inflammation leading to airway remodeling (AR). In children, AR may occur very early prior to the age of 6 years. Treatments to prevent or reverse AR are unknown., Aim: We sought to determine (i) whether short allergenic sensitization at a young age in a mouse model may induce enhanced AR and inflammation compared to adults; (ii) the effect of Montelukast on such AR., Methods: Immature and adult Balb/c mice were sensitized and challenged with ovalbumin. AHR and AR were measured using cultured precision-cut lung slices and inflammation by bronchoalveolar lavage. Experiments were repeated after administration of Montelukast., Results: OVA-challenged mice developed AHR to methacholine regardless of age of first exposure to OVA. Young mice developed greater thickened basement membrane, increased smooth muscle mass, and increased area of bronchovascular fibrosis compared with adult mice. Cellular infiltrates in BAL differed depending upon animal age at first exposure with higher eosinophilia measured in younger animals. Montelukast decreased ASM mass, BAL cellularity., Conclusion: We provide thus evidence for a greater degree of AR after allergenic sensitization and challenge in younger mice versus adults. This study provides proof of concept that airway remodeling can be prevented and reversed in this case by anti-asthmatic drug Montelukast in this model., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
14. [Early lung disease in cystic fibrosis].
- Author
-
Fayon M, Ladipo Y, Galodé F, Debelleix S, and Reix P
- Subjects
- Animals, Bronchiectasis diagnosis, Bronchiectasis physiopathology, Child, Child, Preschool, Cystic Fibrosis therapy, Disease Models, Animal, Early Medical Intervention, Humans, Infant, Infant, Newborn, Lung Diseases therapy, Mucociliary Clearance physiology, Respiratory System physiopathology, Swine, Cystic Fibrosis diagnosis, Cystic Fibrosis physiopathology, Lung Diseases diagnosis, Lung Diseases physiopathology
- Abstract
Recent data has shown that lung inflammation and infection subvene very early in very young infants with Cystic Fibrosis (CF). This leads to impaired lung function and structural damage, even in asymptomatic children. In the CF-pig model constitutional airway narrowing is present at birth, and is associated with defective mucus migration, and impaired bacterial clearance. At the age of 3 months, 25% of screened CF infants show decreased lung function. Air trapping is also present in 68% and bronchiectasis in 28% of patients. At the same age, the presence of neutrophil elastase in the bronchoalveolar lavage is an ominous sign since it triples the risk of bronchiectasis at the age of 3 years. Since only very few drug therapies have been validated in the preschool children, adapted clinical trials are warranted in this age group. Early interventions may have a huge impact on the natural history of CF, on the condition of not interfering with normal lung growth., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
15. Persistent Infection Because of Pandoraea sputorum in a Young Cystic Fibrosis Patient Resistant to Antimicrobial Treatment.
- Author
-
Pugès M, Debelleix S, Fayon M, Mégraud F, and Lehours P
- Subjects
- Adolescent, Humans, Male, Anti-Infective Agents pharmacology, Anti-Infective Agents therapeutic use, Burkholderiaceae drug effects, Burkholderiaceae isolation & purification, Cystic Fibrosis complications, Drug Resistance, Bacterial, Gram-Negative Bacterial Infections
- Abstract
We report the case of a 13-year-old boy with cystic fibrosis with a pulmonary exacerbation concomitant to the first isolation of Pandoraea sputorum. The imipenem and trimethoprim-sulfamethoxazole treatments failed, with persistence of the bacteria, bronchial congestion and a decline in lung function. Pandoraea sp. is rarely isolated, with only 10 cases reported in France in 2011.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.